A Response to: Letter to the Editor Regarding Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials.
作者信息
Wright Grace C, Mysler Eduardo, Yndestad Arne, Kinch Cassandra D, Ogdie Alexis
机构信息
Grace C. Wright MD PC and Association of Women in Rheumatology, New York, NY, USA.
Division of Rheumatology, Organización Médica de Investigación, Buenos Aires, Argentina.
出版信息
Rheumatol Ther. 2025 Jun;12(3):595-596. doi: 10.1007/s40744-025-00751-z. Epub 2025 Mar 17.
Abstract
摘要
相似文献
1
A Response to: Letter to the Editor Regarding Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials.对《致编辑的信：关于种族对托法替布治疗类风湿关节炎疗效和安全性的影响——汇总临床试验的事后分析》的回应
Rheumatol Ther. 2025 Jun;12(3):595-596. doi: 10.1007/s40744-025-00751-z. Epub 2025 Mar 17.
2
Letter to the Editor Regarding the Article "Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials".致编辑的信：关于文章《种族对托法替布治疗类风湿关节炎疗效和安全性的影响：汇总临床试验的事后分析》
Rheumatol Ther. 2025 Jun;12(3):593-594. doi: 10.1007/s40744-025-00750-0. Epub 2025 Mar 15.
3
Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials.种族对托法替布治疗类风湿关节炎疗效和安全性的影响：汇总临床试验的事后分析
Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.
4
Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).剂量调整对托法替布治疗类风湿关节炎患者疗效和安全性的影响：一项开放性、长期扩展研究（ORAL Sequel）的事后分析。
Clin Rheumatol. 2022 Apr;41(4):1045-1055. doi: 10.1007/s10067-021-05908-z. Epub 2022 Jan 1.
5
Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials.托法替布在类风湿关节炎合并可能存在抑郁/焦虑患者中的疗效：3期及3b/4期随机对照试验的事后分析
Rheumatol Ther. 2024 Feb;11(1):35-50. doi: 10.1007/s40744-023-00612-7. Epub 2023 Nov 5.
6
Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.托法替布治疗亚太地区类风湿关节炎患者的疗效和安全性：汇总临床研究数据的事后分析。
Int J Rheum Dis. 2019 Jun;22(6):1094-1106. doi: 10.1111/1756-185X.13516. Epub 2019 Mar 22.
7
Letter to the Editor Regarding "Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance".致编辑的信：关于“托法替布与肿瘤坏死因子抑制剂安全性和疗效的地理差异：ORAL Surveillance事后分析”
Rheumatol Ther. 2025 Apr;12(2):401-402. doi: 10.1007/s40744-024-00740-8. Epub 2025 Jan 20.
8
Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials.托法替布治疗类风湿关节炎患者的疗效和安全性：Ⅱ/Ⅲ期临床试验的事后分析。
Arthritis Res Ther. 2023 Nov 2;25(1):214. doi: 10.1186/s13075-023-03154-z.
9
A Response to: Letter to the Editor Regarding "Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance".对《致编辑的信：关于托法替布与肿瘤坏死因子抑制剂安全性和有效性的地理差异：ORAL Surveillance的事后分析》的回复
Rheumatol Ther. 2025 Apr;12(2):403-405. doi: 10.1007/s40744-024-00739-1. Epub 2025 Jan 20.
10
Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.托法替布（背景甲氨蝶呤剂量）治疗银屑病关节炎的疗效和安全性：两项 III 期临床试验的事后探索性分析。
Clin Rheumatol. 2022 Feb;41(2):499-511. doi: 10.1007/s10067-021-05894-2. Epub 2021 Sep 12.
本文引用的文献
1
Letter to the Editor Regarding the Article "Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials".致编辑的信：关于文章《种族对托法替布治疗类风湿关节炎疗效和安全性的影响：汇总临床试验的事后分析》
Rheumatol Ther. 2025 Jun;12(3):593-594. doi: 10.1007/s40744-025-00750-0. Epub 2025 Mar 15.
2
Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials.种族对托法替布治疗类风湿关节炎疗效和安全性的影响：汇总临床试验的事后分析
Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.
3
Demographic diversity of participants in Pfizer sponsored clinical trials in the United States.辉瑞赞助的美国临床试验参与者的人口统计学多样性。
Contemp Clin Trials. 2021 Jul;106:106421. doi: 10.1016/j.cct.2021.106421. Epub 2021 Apr 30.
Zotero 插件